American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
China said on Saturday it strongly opposes Washington's decision to levy additional tariffs on $550 billion worth of Chinese goods and warned the United States of consequences...Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Despite a drop in biotech stocks this week after political talk about price gouging, an analyst said Wednesday that the sector remains a good investment.
"Biotech and even specialty pharmaceuticals is still a stock picker's paradise," Corey Davis of Canaccord Genuity told CNBC's "Power Lunch. "
Price gouging has come to the forefront of news this week with commentary from Clinton as well as the controversy surrounding the drug Daraprim.
Davis attributes most of the downtick in the stocks to Clinton's tweet and subsequent rhetoric.
"It makes for great political rhetoric but at the end of the day, I don't think that any of these proposals are anything new or dramatic," he said about Clinton's proposed legislation. "I just don't think at the end of they day they're going pass and even if they do they're not going to have a material effect on the biopharm industry."
His top stock pick in the sector is Pacira Pharmaceuticals because, "it's been unduly beaten up and it's got a drug on the market and it's going to rebound nicely soon."
Disclosures: Neither Davis nor Canaccord Genuity own shares of Pacira Pharmaceuticals.